Words such as “believes,” “plans,” “can,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities and benefits of using RNA profiling in the drug discovery process, results that may be implied from prior results, the goals of HTG transcriptome-informed drug discovery approach and the ability to achieve those goals, and the design and potential benefits of HTG’s RNA platform technologies. For more information visit Forward-Looking Statements: Giannini Fellowship to support his research with Professor Howard Chang.īuilding on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. He then transitioned to postdoctoral studies at Stanford University and was awarded the A.P. degree in Chemistry at the University of Rochester in 2009, as an Elon Huntington Hooker Fellow with Professor Joseph Wedekind. He is also a vital part of the development of the planned School of Pharmacy and Pharmaceutical Sciences, having served on the Pharmacy Planning group responsible for creating proposals to the UCI Senate, UC System, and the Accreditation Council for Pharmacy Education (ACPE). Beyond his research accomplishments, he has been an active presence in the UCI community as the Director of the RNA Club and its annual symposium, a co-founder of the Chemical and Systems Biology Club and the faculty advisor for the Pharm Sci undergraduate student council. Spitale’s research has focused on developing novel chemical and bioinformatic approaches toward understanding the role of RNA structure and function in normal biology as well as disease. After joining UCI Pharmaceutical Sciences Department as an Assistant Professor in 2014, he was promoted to Associate Professor in 2018, and rose to the ranks of Professor in 2020. Spitale currently serves as the Associate Director and Associate Dean of Research in the School of Pharmacy & Pharmaceutical Sciences at University of California, Irvine (UCI). A video providing an overview of HTG’s Therapeutics business and a link to the replay of initial presentation in this KOL series are available on the Company’s website HERE.Ī live question and answer session will follow the presentations. The goal of this approach is to enable the selection and characterization of de-risked candidate molecules across selected therapeutic targets of interest leading to potential business development and licensing opportunities in various therapeutic areas. HTG Therapeutics, the company’s drug discovery business unit, is actively using its transcriptome-informed approach to drug discovery to design and further refine small-molecule chemical libraries. Specifically, differential regulation of the ferroptosis pathway by structurally similar compounds that target mTOR will be offered as an example of how RNA profiling can aid in understanding post-target engagement consequences and expand our understanding of the biological implications of compound treatment. Robert Spitale, PhD, from the University of California - Irvine, discussing the use of RNA profiling in the drug discovery process to better uncover mechanism of action and refine the drug screening processes.Īdditionally, the HTG Therapeutics team will present results from the application of its transcriptome-informed drug discovery process. This latest webinar features a presentation from KOL, Dr. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced it will host its next HTG Therapeutics key opinion leader (KOL) webinar: “ The Role of RNA Profiling in Drug Discovery and Analysis”, on Tuesday, Decemat 11:00 am Eastern Standard Time. 09, 2022 (GLOBE NEWSWIRE) - HTG Molecular Diagnostics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |